BBLG logo

Bone Biologics Corporation Stock Price

NasdaqCM:BBLG Community·US$2.1m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

BBLG Share Price Performance

US$1.16
-4.12 (-78.03%)
US$1.16
-4.12 (-78.03%)
Price US$1.16

BBLG Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with moderate risk.

5 Risks
0 Rewards

Bone Biologics Corporation Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$3.1m

Other Expenses

-US$3.1m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-1.73
0%
0%
0%
View Full Analysis

About BBLG

Founded
2004
Employees
2
CEO
Jeffrey Frelick
WebsiteView website
www.bonebiologics.com

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Recent BBLG News & Updates

Recent updates

No updates